Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, raised $44 million by offering 5.5 million shares (up from 5.0 million) at $8, as expected. Celladon Corporation plans to list on the NASDAQ under the symbol CLDN. Celladon Corporation initially filed confidentially on 9/6/2013. Barclays acted as the sole bookrunner on the deal.
